Kevin Grogan is the Managing Editor Europe at Commercial. He specializes in various aspects of medicine and healthcare, with a focus on pharmaceuticals, medical technology, and healthcare technology, including topics like gene therapy, immunology, and digital health. Kevin's work has been featured in Informa and Citeline.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kevin Grogan's articles predominantly focus on the healthcare and pharmaceutical industries, specifically covering press releases, private sector announcements, industry-specific news, and government announcements. His coverage also includes scientific topics related to drug development and biotech sectors.
Given this focus, Kevin is likely to be interested in receiving pitches that provide insights into new drug developments, clinical trials advancements, or significant healthcare deals. He may particularly appreciate access to exclusive data or expert commentary from industry professionals with insider knowledge of recent developments within the pharmaceutical field.
It's clear that Kevin has a strong interest in both scientific breakthroughs and business-related news within the pharmaceutical and biotech sectors. Therefore, individuals or organizations aiming to reach out should consider offering unique angles on these themes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
As the Oxford-headquartered firm raises $310m, CEO Ros Deegan tells Scrip about its hopes to produce a broad pipeline across endocrinology and immunology.
The company has sold two rare pediatric disease priority review vouchers in the space of a week.
Building on Phase Ib/II data, and having received FDA fast track Designation, Nouscom is set to initiate a registration-enabling trial for its off-the-shelf neoantigen-based vaccine.
By: Alexandra Shimmings, Kevin Grogan
ESMO takes place in Madrid from Oct. 23-27. Late-breaking data from novel cancer vaccines to next-generation KRAS G12C inhibitors and new antibody-drug conjugates will show whether next-generation challengers can beat established standards of care. Scrip previews key readouts.
The UK company is buying the Netherlands-based biotech that was once coveted by Pfizer for what could prove to be a bargain.
CEO David Loew has told analysts that the French firm has "a focused pipeline with multiple opportunities capable of becoming meaningful new medicines."
By: Kevin Grogan
The Madrid meeting rose to acclaim data “of a magnitude not previously seen” for a combo set to become first-line maintenance standard of care for extensive stage small cell lung cancer.
The Swiss company's candidate has comfortably surpassed Lumakras and Krazati; significant survival data and an impressive safety profile screams standard of care potential in previously treated KRAS G12C-mutated lung cancer.
The full dataset from HARMONi-GI1 will provide the basis for a China filing in biliary tract cancer of the anti-PD-1 x VEGF bispecific antibody, which is already approved in the country for lung cancer.
The TROP2-directed antibody-drug conjugate cut risk of death by 32% in advanced endometrial cancer in the TroFuse-005 trial.
